Track protection status across key markets to assess launch feasibility.
It is formulated by 3 pharmaceutical companies such as TAIHO ONCOLOGY, NATCO, MSN. It is marketed under 2 brand names, including LONSURF, TIPIRACIL HYDROCHLORIDE AND TRIFLURIDINE. Available in 2 different strengths, such as EQ 6.14MG BASE;15MG, EQ 8.19MG BASE;20MG, and administered through 1 route including TABLET;ORAL.
API availability: Loading API feasibility...
Licensing: 3 potential partnersUS Launch window: Loading launch window...
Stay ahead with worldwide patent expiry and latest updates.
FDA approval history for this ingredient
Stay ahead with worldwide patent expiry insights, exclusivity data, and latest updates.
Key expiration dates for US patents covering this ingredient
Stay ahead with worldwide patent expiry insights, market data, and research updates.
Latest drug strengths approved by FDA
Strength | Route of Administration | Companies | Latest Approval Date |
---|
Patents approved by the FDA for the ingredient
|
Patent Number | Publication Date | Legal Status | Patent Expiry Date | |
---|---|---|---|---|---|
{"application_id":"95927","ingredient":"TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE","trade_name":"LONSURF","family_id":"4b6c539f93a846e596f3","publication_number":"USRE46284E1","cleaned_patent_number":"RE46284","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2029-09-22","publication_date":"2017-01-24","legal_status":"Patented case"} | USRE46284E1 | 24 Jan, 2017 | Patented case | 22 Sep, 2029 | |
{"application_id":"2806","ingredient":"TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE","trade_name":"LONSURF","family_id":"08c16383fec449298e00","publication_number":"US10457666B2","cleaned_patent_number":"10457666","drug_product_flag":"Y","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2034-06-17","publication_date":"2019-10-29","legal_status":"Patented case"} | US10457666B2 Molecular Formulation | 29 Oct, 2019 | Patented case | 17 Jun, 2034 | |
{"application_id":"2786","ingredient":"TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE","trade_name":"LONSURF","family_id":"08c16383fec449298e00","publication_number":"US9527833B2","cleaned_patent_number":"9527833","drug_product_flag":"Y","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2034-06-17","publication_date":"2016-12-27","legal_status":"Expired"} | US9527833B2 Molecular Formulation | 27 Dec, 2016 | Expired | 17 Jun, 2034 | |
{"application_id":"116619","ingredient":"TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE","trade_name":"LONSURF","family_id":"c2bfca045fd6404e9723","publication_number":"US9943537B2","cleaned_patent_number":"9943537","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2034-09-05","publication_date":"2018-04-17","legal_status":"Granted"} | US9943537B2 | 17 Apr, 2018 | Granted | 05 Sep, 2034 | |
{"application_id":"95928","ingredient":"TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE","trade_name":"LONSURF","family_id":"0fd077b30b4e4df88adf","publication_number":"US10456399B2","cleaned_patent_number":"10456399","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2037-02-03","publication_date":"2019-10-29","legal_status":"Granted"} | US10456399B2 | 29 Oct, 2019 | Granted | 03 Feb, 2037 | |
{"application_id":"95940","ingredient":"TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE","trade_name":"LONSURF","family_id":"0fd077b30b4e4df88adf","publication_number":"US10960004B2","cleaned_patent_number":"10960004","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2037-02-03","publication_date":"2021-03-30","legal_status":"Granted"} | US10960004B2 | 30 Mar, 2021 | Granted | 03 Feb, 2037 |
Latest clinical trials and research studies for this ingredient
NCT ID | Title | Status | Phase | Conditions | Start Date | Completion Date |
---|
Manufacturing Locations
Unlock access to all suppliers of Tipiracil Hydrochloride; Trifluridine
Note: Patent expirations and exclusivity timelines are dynamic and may shift based on litigation, regulatory extensions, and maintenance filings. Regular monitoring is advised.